ISABEL WARRICK: Open Payments
NPI 1295311447 · FORT MYERS, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$449 in 20 payments from 9 companies in 2025. Trend: 2023 $608 · 2024 $754 · 2025 $449
Food & beverage: $449
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 7 | $173 |
| ABBVIE INC. | 3 | $64 |
| Janssen Biotech, Inc. | 2 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $53 |
| Galderma Laboratories, L.P. | 2 | $32 |
| Arcutis Biotherapeutics, Inc. | 1 | $22 |
| Organogenesis Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $16 |
| GENZYME CORPORATION | 1 | $15 |
Products named: DUPIXENT, SKYRIZI, TREMFYA, OTEZLA, NEMLUVIO, Zoryve, PURAPLY WOUND MATRIX, TALTZ.
Industry payments across FL — which companies pay providers there.
